e-learning
resources
Virtual 2021
06.09.2021
Lung disease burden and management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Oral corticosteroid (OCS) risk predictor for osteoporosis
B. Stanley (One Shenton, Singapore), J. Chapaneri (Cambridge, United Kingdom), T. Tran (Gaithersburg, United States of America), E. Maslova (Cambridge, United Kingdom), V. Carter (One Shenton, Singapore), D. Price (One Shenton, Singapore)
Source:
Virtual Congress 2021 – Lung disease burden and management
Session:
Lung disease burden and management
Session type:
E-poster
Number:
2159
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Stanley (One Shenton, Singapore), J. Chapaneri (Cambridge, United Kingdom), T. Tran (Gaithersburg, United States of America), E. Maslova (Cambridge, United Kingdom), V. Carter (One Shenton, Singapore), D. Price (One Shenton, Singapore). Late Breaking Abstract - Oral corticosteroid (OCS) risk predictor for osteoporosis. 2159
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma
Source: International Congress 2019 – Powerful cohort studies with/without lung function
Year: 2019
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Late Breaking Abstract - Use of inhaled corticosteroids and the risk of lung cancer, the HUNT study
Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench
Year: 2017
Late Breaking Abstract - Overuse of oral corticosteroids in asthma – modifiable factors and potential role of biologics
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Late Breaking Abstract - Exacerbation of asthma in childhood: seasonal pattern and risk factors.
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017
Late Breaking Abstract - SABA overuse and risk of mortality in a nationwide Swedish asthma cohort (HERA)
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019
Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Late Breaking Abstract - Overestimation of asthma control and misperception of short-acting ß2-agonists (SABA) use among physicians in Poland
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020
Late Breaking Abstract - Oral corticosteroids exposure in a Swedish nationwide asthma population during 2006-2016
Source: International Congress 2018 – Does asthma phenotyping improve treatment?
Year: 2018
Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy.
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021
Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study
Source: Eur Respir J, 57 (2) 2000515; 10.1183/13993003.00515-2020
Year: 2021
Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia
Source: Virtual Congress 2021 – Diagnosis and management of COVID-19
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept